Recent studies indicate that approximately 30% of patients initially diagnosed with early-stage HR+/HER2- breast cancer will eventually develop distant or metastatic disease (2), highlighting the critical need for effective treatment strategies for this patient population. The gene discussed is ERBB2; the disease is breast carcinoma.